



Date: 16.10.2014

To,

Bombay Stock Exchange Limited

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai - 400 001.

Fax : 022-22723121/2041/ 1072

National Stock Exchange of India Ltd.

Exchange Plaza, 5th Floor,

Plot No. C/1, G block,

Bandra-Kurla Complex,

Bandra (E)

Mumbai - 400 051.

Fax : 022-26598237/38

Ref: Scrip ID - SHARONBIO Scrip Code 532908

**Sub: Intimation regarding United Kingdom - Medicine & Health Care
Product Regulatory Agency (UKMHRA) inspection conducted for Good
Manufacturing Practices (GMP) for our recently Expanded
Formulation Plant area located at Uttarakhand.**

Dear Sir/Madam,

This is to intimate that the *United Kingdom - Medicine & Health Care Product Regulatory Agency (UKMHRA)* team has conducted the inspection for Good Manufacturing Practices (GMP) for our recently expanded Formulation Plant area located at Selaqui, Uttarakhand.

The Intimation from the authorities is expected to be received by November, 2014.

In the view of above it should be noted that after the expansion the production capacity of our Formulation plant located at Selaqui, Uttarakhand has been doubled in the term of production recently.

It would be worth revealing that we had already received the approval from UKMHRA team for Good Manufacturing Practices for Tablets and Capsules for our existing formulation plant located at Selaqui, Uttarakhand. The same was intimated to BSE & NSE as on 24th June, 2014.

Thanking you.

Yours truly

For Sharon Bio-Medicine Limited

Mohan P. Kala

Director

DIN: 00118143

